A Risk-Benefit Assessment of Sildenafil in the Treatment of Erectile Dysfunction

被引：0
|
作者：
Dinko Vitezic
机构：
[1] University of Rijeka Medical School,Clinical Pharmacology, Department of Pharmacology
[2] and Department for Science and Clinical Pharmacology,undefined
[3] University Hospital Centre Rijeka,undefined
来源：
Drug Safety | 2001年 / 24卷
关键词：
Erectile Dysfunction; Phentolamine; Priapism; Alprostadil; Intracavernosal Injection;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Sildenafil is an oral treatment for erectile dysfunction (ED). It acts as an inhibitor of 3′,5′-cyclic guanosine monophosphate-phosphodiesterase type 5. An effective treatment for ED is required to produce an erectile response sufficient for satisfactory sexual performance. This has been documented for sildenafil in men with ED of differing aetiologies and baseline severity in various types of clinical trials.
引用
收藏
页码：255 / 265
页数：10
相关论文
共 50 条
  • [1] A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction
    Vitezic, D
    [J]. DRUG SAFETY, 2001, 24 (04) : 255 - 265
  • [2] Men with Mild Erectile Dysfunction Benefit from Sildenafil Treatment
    Benard, Francois
    Carrier, Serge
    Lee, Jay C.
    Talwar, Varun
    Defoy, Isabelle
    [J]. JOURNAL OF SEXUAL MEDICINE, 2010, 7 (11): : 3725 - 3735
  • [3] MEN WITH MILD ERECTILE DYSFUNCTION BENEFIT FROM SILDENAFIL TREATMENT
    Carrier, Serge
    Benard, Francois
    Lee, Jay C.
    Talwar, Varun
    Defoy, Isabelle
    [J]. JOURNAL OF SEXUAL MEDICINE, 2010, 7 : 19 - 19
  • [4] Men with mild erectile dysfunction benefit from sildenafil treatment
    Carrier, S.
    Benard, F.
    Lee, J. C.
    Talwar, V
    Defoy, I
    [J]. JOURNAL OF SEXUAL MEDICINE, 2009, 6 : 447 - 447
  • [5] Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis
    Hsu, J. C.
    Tang, D. H.
    Lu, C. Y.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2015, 69 (04) : 436 - 443
  • [6] QUANTITATIVE RISK-BENEFIT ANALYSIS OF ORAL PHOSPHODIESTERASE TYPE 5 INHIBITORS ON ERECTILE DYSFUNCTION TREATMENT
    Hsu, J. C.
    Tang, D.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A283 - A283
  • [7] Sildenafil in the treatment of erectile dysfunction
    Schwartz, I
    McCarthy, D
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (10): : 699 - 700
  • [8] Treatment of erectile dysfunction with sildenafil
    Marks, LS
    Duda, C
    Dorey, FJ
    Macairan, ML
    Santos, PB
    [J]. UROLOGY, 1999, 53 (01) : 19 - 24
  • [9] A risk-benefit assessment of mirtazapine in the treatment of depression
    Kasper, S
    PraschakRieder, N
    Tauscher, J
    Wolf, R
    [J]. DRUG SAFETY, 1997, 17 (04) : 251 - 264
  • [10] A Risk-Benefit Assessment of Octreotide in the Treatment of Acromegaly
    Aart Jan van der Lely
    Wouter W. de Herder
    Steven W. J. Lamberts
    [J]. Drug Safety, 1997, 17 : 317 - 324
12345